Table 2.

Randomized trials of first-line anti-EGFR antibody treatment in mCRC [35, 36, 48 – 53]

	Treatment	PFS, months	OS, months	ORR, %
KRAS wiid-type
CRYSTAL (n = 666) [35]	FOLFIRI ± cetuximab	9.9 vs. 8.4	23.5 vs. 20.0	57 vs. 40
		HR = 0.696	HR = 0.796	p (CMH test) < 0.001
		p (log-rank test) = 0.0012	p (log-rank test) = 0.0093
PRIME (n = 656) [48]	FOLFOX ± panitumumab	10.0 vs. 8.6	23.9 vs. 19.7	55 vs. 48
		HR = 0.80	HR = 0.83	p (stratified log-rank test) = 0.068
		p (stratified log-rank test) = 0.02	p (stratified log-rank test) = 0.072
OPUS (n = 179) [49]	FOLFOX ± cetuximab	8.3 vs. 7.2	22.8 vs. 18.5	57 vs. 34
		HR = 0.567	HR = 0.855	p (stratified CMH test) = 0.0027
		p (stratified log-rank test) = 0.0064	p (stratified log-rank test) = 0.39
COIN (n = 729) [50]	XELOX/FOLFOX± cetuximab	8.6 vs. 8.6	17.9 vs. 17.0	64 vs. 57
		HR = 0.96	HR = 1.04	p (log-rank test) = 0.049
		p (log-rank test) = 0.60	p (log-rank test) = 0.67
NORDIC (n = 126) [51]	FLOX ± cetuximab	8.7 vs. 7.9	22.0 vs. 20.1	47 vs. 46
		HR = 1.07	HR = 1.14	p = 0.89
		p (log-rank test) = 0.66	p (log-rank test) = 0.48
all RAS wild-type
OPUS (n = 78) [52]	FOLFOX ± cetuximab	12.0 vs. 5.8	19.8 vs. 17.8	58 vs. 29
		HR = 0.53	HR = 0.94	p (CMH test) = 0.008
		p (log-rank test) = 0.062	p (log-rank test) = 0.80
CRYSTAL (n = 367) [53]	FOLFIRI ± cetuximab	11.4 vs. 8.4	28.4 vs. 20.2	66 vs. 39
		HR = 0.56	HR = 0.69	p < 0.000
		p = 0.0002	p = 0.0024
PRIME (n = 512) [36]	FOLFOX ± panitumumab	10.1 vs. 7.9	26.0 vs. 20.2	n.a.
		HR = 0.72	HR = 0.78
		p = 0.004	p = 0.04

CMH = Cochran-Mantel-Haenszel; n.a. = not assessed.